Traws Pharma Announced KPMG As The New Auditor; Here’s What You Need To Know

Traws Pharma, Inc., formerly Onconova Therapeutics (NASDAQ), has appointed KPMG LLP as its new independent registered public accounting firm, effective Monday. This change precedes the company’s fiscal year ending December 31, 2024. The Audit Committee of the Board of Directors made this decision on Monday, signaling a major shift for the Delaware-based pharmaceutical company. This move comes after a period in which Traws Pharma did not seek KPMG’s counsel on any significant accounting or auditing issues relevant to their financial reporting. Importantly, there were no disagreements or notable issues between Traws Pharma and KPMG during the fiscal years 2023 and 2022 that would necessitate disclosure under SEC guidelines.

In compliance with SEC regulations, Traws Pharma has secured a confirmation letter from its previous auditor, Ernst & Young LLP. This letter, affirming their agreement with the statements about their previous engagement, was issued today and has been submitted to the SEC as part of the Form 8-K filing. Traws Pharma, listed on Nasdaq under the ticker NASDAQ and based in Newtown, PA, is led by Chief Financial Officer Mark Guerin. This change in auditors is part of Traws Pharma’s commitment to upholding strong financial practices and ensuring transparency for its stakeholders. Details of this transition have been documented in the company’s latest SEC filing.